Format

Send to

Choose Destination
Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 107(5):85-87. Epub 2017 Sep 28.

Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain.

Author information

1
Department of Internal Medicine, Division of Rheumatology, Rush University Medical Center, Chicago IL, USA.
2
Department of Internal Medicine, Division of Rheumatology, Rush University Medical Center, Chicago IL, USA. joel_block@rush.edu.

Abstract

Blockade of nerve growth factor (NGF) with antibodies is a promising strategy for treatment of chronic pain associated with osteoarthritis (OA). This narrative review describes the current status of NGF-blockade for the treatment of OA pain. We summarise briefly current evidence for the efficacy and risks of anti-NGF blockade. Two anti-NGF antibodies, tanuzemab and fasinumab, are in active development, with tanuzemabclose to completing Phase 3 trials in preparation for an application for approval for clinical use.

PMID:
28967370
PMCID:
PMC6007861
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Clinical and Experimental Rheumatology Icon for PubMed Central
Loading ...
Support Center